CN109528664B - Lyophilized powder containing ubenimex-antitumor drug synergistic prodrug derivative and preparation method thereof - Google Patents
Lyophilized powder containing ubenimex-antitumor drug synergistic prodrug derivative and preparation method thereof Download PDFInfo
- Publication number
- CN109528664B CN109528664B CN201811574582.9A CN201811574582A CN109528664B CN 109528664 B CN109528664 B CN 109528664B CN 201811574582 A CN201811574582 A CN 201811574582A CN 109528664 B CN109528664 B CN 109528664B
- Authority
- CN
- China
- Prior art keywords
- ubenimex
- excipient
- freeze
- drug
- active component
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229940002612 prodrug Drugs 0.000 title claims abstract description 21
- 239000000651 prodrug Substances 0.000 title claims abstract description 21
- 239000008176 lyophilized powder Substances 0.000 title claims description 8
- 238000002360 preparation method Methods 0.000 title abstract description 21
- 230000002195 synergetic effect Effects 0.000 title abstract description 15
- 239000002246 antineoplastic agent Substances 0.000 title description 19
- 229940041181 antineoplastic drug Drugs 0.000 title description 18
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 24
- 239000003814 drug Substances 0.000 claims abstract description 23
- 229940079593 drug Drugs 0.000 claims abstract description 20
- VGGGPCQERPFHOB-MCIONIFRSA-N Bestatin Chemical class CC(C)C[C@H](C(O)=O)NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1 VGGGPCQERPFHOB-MCIONIFRSA-N 0.000 claims abstract 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- 238000011282 treatment Methods 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 19
- 239000011550 stock solution Substances 0.000 claims description 19
- 239000008215 water for injection Substances 0.000 claims description 18
- 238000001035 drying Methods 0.000 claims description 14
- 230000008014 freezing Effects 0.000 claims description 14
- 238000007710 freezing Methods 0.000 claims description 14
- 238000010438 heat treatment Methods 0.000 claims description 14
- 238000003756 stirring Methods 0.000 claims description 11
- 239000008186 active pharmaceutical agent Substances 0.000 claims description 8
- 238000000859 sublimation Methods 0.000 claims description 7
- 230000008022 sublimation Effects 0.000 claims description 7
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 5
- 229930195725 Mannitol Natural products 0.000 claims description 5
- 239000000594 mannitol Substances 0.000 claims description 5
- 235000010355 mannitol Nutrition 0.000 claims description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 4
- 239000008103 glucose Substances 0.000 claims description 4
- 239000008101 lactose Substances 0.000 claims description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
- 230000000118 anti-neoplastic effect Effects 0.000 claims description 2
- 239000000843 powder Substances 0.000 abstract description 15
- 239000000203 mixture Substances 0.000 abstract description 12
- 230000000259 anti-tumor effect Effects 0.000 abstract description 8
- 238000001727 in vivo Methods 0.000 abstract description 6
- 150000003839 salts Chemical class 0.000 abstract description 4
- 230000014759 maintenance of location Effects 0.000 abstract description 3
- 230000003287 optical effect Effects 0.000 abstract description 3
- 229950009811 ubenimex Drugs 0.000 description 50
- 150000001875 compounds Chemical class 0.000 description 40
- VGGGPCQERPFHOB-RDBSUJKOSA-N (2s)-2-[[(2s,3r)-3-amino-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1 VGGGPCQERPFHOB-RDBSUJKOSA-N 0.000 description 25
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 24
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 12
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 12
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 11
- 229960000684 cytarabine Drugs 0.000 description 11
- 230000005764 inhibitory process Effects 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 10
- 229960001904 epirubicin Drugs 0.000 description 10
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 9
- UOHPEWIBMAQKCN-UHFFFAOYSA-N 1,3,5,5,6-pentafluoro-1,3-diazinane-2,4-dione Chemical compound FC1C(C(N(C(N1F)=O)F)=O)(F)F UOHPEWIBMAQKCN-UHFFFAOYSA-N 0.000 description 8
- 229960002949 fluorouracil Drugs 0.000 description 8
- 238000004108 freeze drying Methods 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 7
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 102100022749 Aminopeptidase N Human genes 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 229960004942 lenalidomide Drugs 0.000 description 6
- 208000032839 leukemia Diseases 0.000 description 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 6
- QZDDFQLIQRYMBV-UHFFFAOYSA-N 2-[3-nitro-2-(2-nitrophenyl)-4-oxochromen-8-yl]acetic acid Chemical compound OC(=O)CC1=CC=CC(C(C=2[N+]([O-])=O)=O)=C1OC=2C1=CC=CC=C1[N+]([O-])=O QZDDFQLIQRYMBV-UHFFFAOYSA-N 0.000 description 5
- 108010049990 CD13 Antigens Proteins 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 206010060862 Prostate cancer Diseases 0.000 description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 4
- 238000006555 catalytic reaction Methods 0.000 description 4
- 238000003795 desorption Methods 0.000 description 4
- 238000011049 filling Methods 0.000 description 4
- 210000004051 gastric juice Anatomy 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- PKZFFNJDFBBUIS-ZSCHJXSPSA-N (2s)-2-amino-4-methylpentanoic acid;4-nitroaniline Chemical compound CC(C)C[C@H](N)C(O)=O.NC1=CC=C([N+]([O-])=O)C=C1 PKZFFNJDFBBUIS-ZSCHJXSPSA-N 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 208000034578 Multiple myelomas Diseases 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000002045 lasting effect Effects 0.000 description 3
- 201000007270 liver cancer Diseases 0.000 description 3
- 208000014018 liver neoplasm Diseases 0.000 description 3
- 230000003285 pharmacodynamic effect Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000013112 stability test Methods 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 2
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 201000003707 ovarian clear cell carcinoma Diseases 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- WTSKMKRYHATLLL-UHFFFAOYSA-N (6-benzoyloxy-3-cyanopyridin-2-yl) 3-[3-(ethoxymethyl)-5-fluoro-2,6-dioxopyrimidine-1-carbonyl]benzoate Chemical compound O=C1N(COCC)C=C(F)C(=O)N1C(=O)C1=CC=CC(C(=O)OC=2C(=CC=C(OC(=O)C=3C=CC=CC=3)N=2)C#N)=C1 WTSKMKRYHATLLL-UHFFFAOYSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical class O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- AOCCBINRVIKJHY-UHFFFAOYSA-N Carmofur Chemical compound CCCCCCNC(=O)N1C=C(F)C(=O)NC1=O AOCCBINRVIKJHY-UHFFFAOYSA-N 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 241000218589 Streptomyces olivaceus Species 0.000 description 1
- 241000970901 Streptomyces olivoreticuli Species 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000007537 Type II DNA Topoisomerases Human genes 0.000 description 1
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001399 anti-metabolic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000008236 biological pathway Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- -1 glycoside compound Chemical class 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000000091 immunopotentiator Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 208000022013 kidney Wilms tumor Diseases 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000012430 stability testing Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to the field of pharmaceutical chemistry, and discloses a freeze-dried powder containing ubenimex-antiedemic drug synergistic prodrug derivatives and a preparation method thereof. The freeze-dried powder contains a pharmaceutical active component and an excipient, wherein the mass ratio of the pharmaceutical active component to the excipient is 1: 0.5-6, wherein the pharmaceutical active component is a prodrug derivative of ubenimex or an optical isomer, a diastereoisomer, a racemic mixture and pharmaceutically acceptable salts thereof. The freeze-dried powder containing the ubenimex-antiedemic drug synergistic prodrug derivative can prolong the retention time of the drug in vivo, improve the pharmacokinetic property of the drug and improve the bioavailability of the drug, thereby achieving better antitumor effect.
Description
Technical Field
The invention relates to the field of medicinal chemistry, in particular to lyophilized powder containing ubenimex-antitumor drug synergistic prodrug derivatives and a preparation method thereof.
Background
Ubenimex (Bestatin) is a dipeptide-structured compound found in the culture broth of Streptomyces olivaceus (Streptomyces olivoreticuli), and is marketed in 1987 as an immunopotentiator in Japan for the treatment of leukemia; ubenimex was marketed domestically in 1998. Ubenimex can inhibit APN activity (IC50 is 2.5-16.9 mu M), can block the effect of tumor stem cells, but hardly has the capacity of inhibiting the proliferation of tumor cells, so that the combined application of ubenimex and other cell antitumor drugs can greatly improve the curative effect of ubenimex. Literature research shows that the combined use of ubenimex and pentafluorouracil in a mouse liver cancer transplantation tumor experiment is obviously better than the independent and separate use of tumor inhibition activities (J Clin Invest 2010, 120, 3326-one 3339), and the research provides a good experimental basis for the combined application of ubenimex and other chemotherapeutic drugs. Clinically, ubenimex can be used in combination with chemotherapy, radiotherapy and in combination with leukemia, multiple myeloma, myelodysplastic syndrome, and other solid tumors.
5-fluorouracil (5-fluorouracil, 5FU) is a class of anti-metabolic antitumor drugs widely applied to clinic, has definite anti-tumor effect and is always used as the first choice drug for treating gastric cancer, rectal cancer, breast cancer and the like. However, the defects of serious bone marrow suppression and gastrointestinal reaction, short half-life period, poor selectivity and the like in the use of 5-fluorouracil limit the wide application of the 5-fluorouracil. In recent years, researchers have reduced or avoided 5FU deficiency by various approaches, and many prodrugs of 5FU have been synthesized and some have been used clinically, such as FTO, HCFU, CAP, 5' dFUrd, BOF-A2, ATFU, etc. In addition, N of 5FU3The urea derivative of (a) forms a prodrug 5FU by the elimination principle, which is as follows:
lenalidomide (Lenalidomide) was developed by Gelgene, usa and is a derivative of thalidomide and is used clinically for the treatment of myelodysplastic syndrome and for the treatment of multiple myeloma in combination with dexamethasone. Lenalidomide has an effect on various biological pathways within the cell. The clinical I, II stage research shows that the compound has inhibition effect on various tumors, including multiple myeloma, prostatic cancer, thyroid cancer, renal cancer, melanoma, liver cancer and chronic lymphocytic leukemia.
Epirubicin (Epirubicin) is an antibiotic antineoplastic drug and has a structure of an isomer of doxorubicin. The main anti-tumor action mechanism of epirubicin is that epirubicin can be directly inserted between DNA nucleobase pairs to interfere the transcription process, thereby preventing the formation of mRNA and inhibiting the synthesis of DNA and RNA. In addition, the study finds that epirubicin also has an inhibitory effect on topoisomerase II and is a cell cycle nonspecific drug. It is mainly used for various solid tumors such as acute leukemia, nephroblastoma, soft tissue sarcoma, bladder cancer, testicular cancer, prostatic cancer, gastric cancer, malignant lymphoma, breast cancer, bronchogenic carcinoma, ovarian cancer, liver cancer (including primary hepatocellular carcinoma and metastatic cell cancer) and the like in clinic. At present, the combined application of epirubicin is more, such as combining with paclitaxel, combining with sorafenib for advanced breast cancer and the like.
Cytarabine (Cytarabine) is a glycoside compound formed by cytosine and arabinose, is a competitive inhibitor of DNA polymerase, can inhibit the biosynthesis of DNA in vivo, and is mainly used for treating leukemia clinically. However, clinical studies have found that cytarabine has a series of disadvantages: poor lipid solubility, low bioavailability, large toxic and side effects and the like. Therefore, scientists research the related diseases of the combination treatment of the cytarabine and other medicines, thereby improving the medicinal activity and the chemical stability of the cytarabine and greatly improving the clinical curative effect of the cytarabine (the combination of the cytarabine and other medicines such as fludarabine, mitoxantrone and the like for treating various diseases such as leukemia, lymphoma and the like).
The chemical structural formulas of ubenimex (Bestatin), 5-fluorouracil (5-fluorouracil, 5FU), Lenalidomide (Le), Cytarabine (Cytarabine, Cy) and Epirubicin (Epirubicin, Ep) are shown in the specification.
At present, the mutual prodrug becomes an important strategy for designing a medicament aiming at multiple pathogenesis and multiple case links of malignant tumors. The medicine is metabolized and degraded in vivo, releases a plurality of pharmacodynamic structures and then is respectively combined with different action parts to realize the synergistic regulation effect, thereby generating better pharmacodynamic effect, reducing toxic and side effects and the like. The synergistic prodrug has single physicochemical property and uniform pharmacokinetic property compared with the combined drug, and can avoid the problems of interaction among components after the drug is mixed, asynchronous absorption, distribution and metabolism of each component and the like.
Disclosure of Invention
The invention aims to overcome the defects of the existing antitumor active compounds, and provides freeze-dried powder containing ubenimex-antitumor drug synergistic prodrug derivatives and a preparation method thereof.
The invention provides a freeze-dried powder containing ubenimex-antitumor drug synergistic prodrug derivatives, which contains a drug active component and an excipient, wherein the mass ratio of the drug active component to the excipient is 1: 0.5-6, wherein the pharmaceutical active component is a prodrug derivative of ubenimex shown in formula (I) or an optical isomer, a diastereoisomer, a racemic mixture and pharmaceutically acceptable salts thereof,
wherein R in the formula (I) is a compound residue with antitumor activity.
Preferably, R is
Preferably, the mass ratio of the pharmaceutically active component to the excipient is 1: 0.8-2.
Preferably, the excipient is at least one of mannitol, glucose and lactose.
The invention also provides a method for preparing the freeze-dried powder containing the ubenimex-antitumor drug synergistic prodrug derivative, which comprises the following steps:
(1) stirring the active pharmaceutical ingredient, the excipient and the water for injection until the active pharmaceutical ingredient, the excipient and the water for injection are completely dissolved to obtain a freeze-dried stock solution;
(2) pre-freezing the freeze-dried stock solution at-25 to-40 ℃ for 1 to 3 hours, vacuumizing to 5 to 30Pa after freezing, heating to-5 to-15 ℃ at the speed of 1 to 3 ℃ per hour, carrying out sublimation drying treatment for 10 to 20 hours, heating to 20 to 40 ℃ at the speed of 5 to 10 ℃ per hour, and carrying out resolution drying treatment for 5 to 10 hours.
Preferably, the volume ratio of the total amount of the pharmaceutically active component and the excipient to the water for injection is 5-20: 100, more preferably 8 to 15: 100.
in the invention, ubenimex (Bestatin) is fused with other compounds with antitumor activity (such as 5-fluorouracil, lenalidomide, epirubicin and cytarabine) through a urea bond by adopting a pharmacophore split principle, and a series of novel synergistic prodrugs are designed and synthesized. Under the action of in vivo enzyme, ubenimex and another anticancer drug fragment can be metabolized to release ubenimex, ubenimex exerts its stem cell inhibiting effect, and the compound with antitumor activity exerts its specific drug effect, thereby realizing the synergistic effect of the two drugs. Therefore, the freeze-dried powder containing the ubenimex-antineoplastic drug synergistic prodrug derivative can prolong the retention time of the ubenimex-antineoplastic drug in vivo, improve the pharmacokinetic property of the ubenimex-antineoplastic drug and improve the bioavailability of the ubenimex-antineoplastic drug, thereby achieving better antineoplastic effect.
Drawings
FIG. 1 is a liquid chromatogram of compound 5FU-bestatin prepared in preparation example 1;
FIG. 2 is a graph showing the stability of compound 5FU-bestatin prepared in preparation example 1 in artificial gastric juice;
FIG. 3 is a graph showing the stability of compound 5FU-bestatin prepared in preparation example 1 in artificial intestinal juice;
FIG. 4 is a graph showing the stability of compound 5FU-bestatin prepared in preparation example 1 in human plasma.
Detailed Description
The following detailed description of embodiments of the invention refers to the accompanying drawings. It should be understood that the detailed description and specific examples, while indicating the present invention, are given by way of illustration and explanation only, not limitation.
The endpoints of the ranges and any values disclosed herein are not limited to the precise range or value, and such ranges or values should be understood to encompass values close to those ranges or values. For ranges of values, between the endpoints of each of the ranges and the individual points, and between the individual points may be combined with each other to give one or more new ranges of values, and these ranges of values should be considered as specifically disclosed herein.
The freeze-dried powder containing ubenimex-antitumor drug synergistic prodrug derivatives contains active pharmaceutical ingredients and excipients.
In the freeze-dried powder, the mass ratio of the pharmaceutical active component to the excipient is 1: 0.5 to 6, preferably 1: 0.8-2.
In the invention, the active pharmaceutical ingredient is a prodrug derivative of ubenimex shown in formula (I) or optical isomer, diastereoisomer, racemic mixture and pharmaceutically acceptable salt thereof,
wherein R in the formula (I) is a compound residue with antitumor activity.
In a preferred embodiment, in formula (I), R is a 5-fluorouracil residue, a lenalidomide residue, a cytarabine residue or an epirubicin residue, each of which has the following structure:
in the above preferred embodiment, the prodrug derivative of ubenimex as a pharmaceutically active ingredient has the following structural formula:
for the compound of the pentafluorouracil-ubenimex (5FU-Bestatin), the preparation method can comprise the following steps: reacting the pentafluorouracil with triphosgene under the catalysis of activated carbon, and then reacting with ubenimex to obtain the target compound 5 FU-Bestatin.
The specific synthetic route is as follows:
reaction conditions a: BTC, activated carbon, Py,0 ℃, wherein BTC is triphosgene, Py is pyridine
The preparation method comprises the following specific steps:
adding 0.65g of pentafluorouracil (5mmol) into a reaction bottle, adding 20ml of pyridine to completely dissolve the pentafluorouracil, adding 0.65g of activated carbon, slowly adding 0.5g of triphosgene in ice bath, continuously reacting for 1 hour in ice bath, extracting the phosgene, and flushing N2And the process is carried out three times. Under ice-bath, 1.7g of ubenimex (5mmol) was slowly added, followed by reaction at room temperature for 12 hours. The activated carbon was filtered, extracted with ethyl acetate, washed 3 times with 6mol/L hydrochloric acid solution, then washed 3 times with saturated brine, and dried over anhydrous sodium sulfate. And (5) evaporating the ethyl acetate until solid is separated out, putting the ethyl acetate into a refrigerator for crystallization, and filtering to obtain a white product.
For the compound lenalidomide-ubenimex (Le-Bestatin), the preparation method can comprise the following steps: the lenalidomide reacts with triphosgene under the catalysis of activated carbon, and then reacts with ubenimex to obtain the target compound Le-Bestatin.
The synthetic route is as follows:
reaction conditions a: BTC, activated carbon, Py,0 ℃, wherein BTC is triphosgene, Py is pyridine
For the compound cytarabine-ubenimex (Cy-Bestatin), the preparation method can comprise the following steps: reacting cytarabine with triphosgene under the catalysis of activated carbon, and then reacting with ubenimex to obtain a target compound Cy-Bestatin.
The synthetic route is as follows:
reaction conditions a: BTC, activated carbon, Py,0 ℃, wherein BTC is triphosgene and Py is pyridine for the compound epirubicin-ubenimex (Ep-Bestatin), which can be prepared by: the epirubicin reacts with triphosgene under the catalysis of activated carbon and then reacts with ubenimex to obtain the target compound Ep-Bestatin.
The synthetic route is as follows:
reaction conditions a: BTC, activated carbon, Py,0 ℃, wherein BTC is triphosgene, Py is pyridine
The "pharmaceutically acceptable salts" of the present invention are those which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like and are commensurate with a reasonable benefit/risk ratio.
In the present invention, the excipient may be a conventional choice in the art. In a specific embodiment, the excipient is at least one of mannitol, glucose, and lactose.
The invention also provides a method for preparing the freeze-dried powder containing the ubenimex-antitumor drug synergistic prodrug derivative, which comprises the following steps:
(1) stirring the active pharmaceutical ingredient, the excipient and the water for injection until the active pharmaceutical ingredient, the excipient and the water for injection are completely dissolved to obtain a freeze-dried stock solution;
(2) pre-freezing the freeze-dried stock solution at-25 to-40 ℃ for 1 to 3 hours, vacuumizing to 5 to 30Pa after freezing, heating to-5 to-15 ℃ at the speed of 1 to 3 ℃ per hour, carrying out sublimation drying treatment for 10 to 20 hours, heating to 20 to 40 ℃ at the speed of 5 to 10 ℃ per hour, and carrying out resolution drying treatment for 5 to 10 hours.
In the method of the present invention, the volume ratio of the total amount of the pharmaceutically active ingredient and the excipient to the water for injection may be 5 to 20: 100, preferably 8 to 15: 100.
the present invention will be described in detail below by way of examples, but the scope of the present invention is not limited thereto.
Preparation example 1
Adding 0.65g of pentafluorouracil (5mmol) into a reaction bottle, adding 20ml of pyridine to completely dissolve the pentafluorouracil, adding 0.65g of activated carbon, slowly adding 0.5g of triphosgene in ice bath, continuously reacting for 1 hour in ice bath, extracting the phosgene, and flushing N2And the process is carried out three times. Under ice-bath, 1.7g of ubenimex (5mmol) was slowly added, followed by reaction at room temperature for 12 hours. The activated carbon was filtered, extracted with ethyl acetate, washed 3 times with 6mol/L hydrochloric acid solution, then washed 3 times with saturated brine, and dried over anhydrous sodium sulfate. And (3) evaporating ethyl acetate until solid is separated out, putting the ethyl acetate into a refrigerator for crystallization, and filtering to obtain a white product which is the compound 5FU-Bestatin, a white solid and a yield: 36.7%, melting point 165-. MS-ESI: [ M-1 ]]=463.6;[M-1+Na]485.8. The nuclear magnetic resonance hydrogen spectrum data are as follows:
300MHz 1H NMR1(d6-DMSO)δ=0.65(d,J=5.7Hz,3H),0.74(d,J=5.7Hz,2H)1.49(m,1H),2.76-2.82(m,1H),2.88-2.96(m,1H)4.01(m,1H),4.21-4.28(m,1H),4.34-4.21(m,1H),6.69-6.71(d,1H),7.20-7.34(m,5H),7.72(d,1H),8.33(d,1H)9.44(d,1H)12.44(d,1H)12.66(s,1H)。
according to a method similar to that of preparation example 1, a compound Le-Bestatin, a compound Cy-Bestatin and a compound Ep-Bestatin can be prepared.
Test example 1
(1) In vitro enzyme inhibition
1. Materials and methods
Aminopeptidase N, substrate L-leucine-p-nitroaniline (from Sigma Co.)
Preparation of buffer, 12.89gNaH2PO4·2H2Dissolving O in a 1000ml volumetric flask, adding fresh boiled and cooled distilled water to constant volume to obtain 50mM phosphate buffer solution with pH of 7.2, and standing at room temperature for later use; dissolving aminopeptidase N in the buffer solution to prepare a solution with 0.1 IU/mL; substrate L-leucine-p-nitroaniline is dissolved in DMSO to prepare a solution of 16mmol/mL, and the solution is placed in a refrigerator for standby.
2. Experimental procedure
Numbering | Aminopeptidase N solution (μ L) | Substrate solution (μ L) | Buffer solution (mu L) | Inhibitors |
100% of the |
10 | 5 | 185 | 0 |
|
0 | 5 | 195 | 0 |
|
10 | 5 | 145 | 40 |
mu.L of the aminopeptidase N solution, 5. mu.L of the substrate L-leucine-p-nitroaniline solution, and 40. mu.L of the compound at different gradient concentrations were added to a 96-well plate, and 200. mu.L of the mixture was supplemented with 50mM phosphate buffer solution (pH7.2), and 100% of the groups contained no inhibitor. Blank was made up to 200. mu.L with 5. mu.L substrate in buffer. Incubation was carried out at 37 ℃ for 0.5 hour and the absorbance was measured at a wavelength of 405 nm. The inhibition rate was calculated according to the following formula:
the IC50 was obtained for each compound by fitting curves based on the concentration of the compound and the corresponding inhibition using origine 7.5 software, and the results are shown in table 1 below.
TABLE 1
The results of in vitro enzyme inhibition experiments show that the target compound 5FU-Bestatin shows the inhibition effect on aminopeptidase N, and the inhibition activity is equivalent to that of the positive drug ubenimex.
(2) In vitro efficacy test (MTT method)
MTT method is used to detect the growth inhibition rate of the compound on ovarian clear cell carcinoma ES-2 cell strain, human leukemia K562 cell strain, human prostate cancer PC-3 cell strain and human colon cancer HCT-116 cell strain. Cells in exponential growth phase were taken, washed with Hank's solution, and then single cells were digested with 0.02% trypsin + 0.05% EDATA, and viable cells were counted at 95% or more by Trypan blue (Trypan blue) staining. Cells were seeded in 96-well plates at 5000 cells/well and different concentrations of compounds were added (blank for reading wells without cells and 100% for wells without cells, each set of three replicate wells, 5FU-Bestatin as compound positive control). At 37 ℃ and 5%CO2After 48h incubation, 100. mu.L of 5% MTT staining solution was added to each well, and after 4h further incubation, centrifugation was carried out at 2500rpm for 12min, and then the plate was discarded, and DMSO was added at 100. mu.L/well. The OD value of absorbance per well was measured at 570nm (absorption wavelength) and 630nm (auxiliary wavelength) on a microplate reader, and the OD value was measured as OD570-OD630The difference of (a) is calculated. The cell growth inhibition rate was calculated by the following formula (OD value in the formula is OD)570-OD630Difference of (d):
the results are shown in Table 2.
TABLE 2
In vitro pharmacodynamic experiments show that the target compound 5FU-Bestatin has certain proliferation inhibition effect on the cells. Compared with positive control drugs of ubenimex (Bestatin) and pentafluorouracil (5FU), the compound has better proliferation inhibition activity on ovarian clear cell carcinoma ES-2, human leukemia K562, human prostate cancer PC-3 and human colon cancer HCT-116 than ubenimex and pentafluorouracil.
(3) In vitro stability assay (HPLC method)
The compound 5FU-Bestatin is studied by artificial gastric juice, artificial intestinal juice and human plasma, and provides basis for further animal experiments.
The preparation of the artificial gastric juice and the artificial intestinal juice in the experiment refers to the second part of the Chinese pharmacopoeia. Chromatographic conditions are as follows: a venusil XBP C-18 column (4.6 mm. times.150 mm,5 μm); mobile phase: acetonitrile-methanol-0.2% aqueous formic acid (8-47-45, v/v/v); sample introduction amount: 20 mu L of the solution; flow rate: 1.0 mL/min; detection wavelength: 258 nm; column temperature: room temperature; the retention time t of the compound 5FU-Bestatin was 6.133min (shown in FIG. 1).
The stability results of compound 5FU-Bestatin are shown in FIGS. 2, 3 and 4: as can be seen from the figure, the compound 5FU-Bestatin is stable in artificial gastric juice and slowly degrades in artificial intestinal blood and human plasma. Thus, the compound 5FU-Bestatin is expected to be designed to slowly degrade in vivo to release the original drug.
Example 1
Accurately weighing 0.5g of compound 5FU-Bestatin and 0.5g of mannitol in a sterile environment, putting the mixture into a clean preparation container, adding 4ml of water for injection, stirring until the mixture is completely dissolved, then adding the water for injection to 5ml, and stirring uniformly to obtain a freeze-dried stock solution.
Filling the freeze-drying stock solution into a 10ml tube glass bottle, half plugging, and transferring into a freeze dryer for freezing treatment, wherein the specific freeze-drying process comprises the following steps: quickly freezing the freeze-dried stock solution to-30 ℃, lasting for 2 hours, vacuumizing to 15Pa, heating to-10 ℃ at the speed of 2 ℃ per hour, carrying out sublimation drying treatment for 15 hours, heating to 30 ℃ at the speed of 8 ℃ per hour, carrying out desorption drying treatment for 8 hours, fully plugging, and capping to obtain the freeze-dried powder A1.
Example 2
Accurately weighing 0.3g of compound Le-Bestatin and 0.6g of glucose in a sterile environment, putting the mixture into a clean preparation container, adding 4ml of water for injection, stirring the mixture until the mixture is completely dissolved, then adding the water for injection to 5ml, and stirring the mixture uniformly to obtain a freeze-dried stock solution.
Filling the freeze-drying stock solution into a 10ml tube glass bottle, half plugging, and transferring into a freeze dryer for freezing treatment, wherein the specific freeze-drying process comprises the following steps: quickly freezing the freeze-dried stock solution to-40 ℃, lasting for 1 hour, vacuumizing to 30Pa, heating to-15 ℃ at the speed of 1 ℃ per hour, carrying out sublimation drying treatment for 10 hours, heating to 20 ℃ at the speed of 5 ℃ per hour, carrying out desorption drying treatment for 5 hours, fully plugging, and capping to obtain the freeze-dried powder A2.
Example 3
Accurately weighing 0.5g of compound Cy-Bestatin and 0.4g of lactose in a sterile environment, placing in a clean preparation container, adding 4ml of water for injection, stirring until the water is completely dissolved, adding 5ml of water for injection, and stirring uniformly to obtain a freeze-dried stock solution.
Filling the freeze-drying stock solution into a 10ml tube glass bottle, half plugging, and transferring into a freeze dryer for freezing treatment, wherein the specific freeze-drying process comprises the following steps: quickly freezing the freeze-dried stock solution to-25 ℃, lasting for 3 hours, vacuumizing to 10Pa, heating to-5 ℃ at the speed of 3 ℃ per hour, carrying out sublimation drying treatment for 20 hours, heating to 40 ℃ at the speed of 10 ℃ per hour, carrying out desorption drying treatment for 10 hours, fully plugging, and capping to obtain the freeze-dried powder A3.
Example 4
Accurately weighing 0.4g of compound Ep-Bestatin and 0.6g of mannitol in a sterile environment, putting the mixture into a clean preparation container, adding 4ml of water for injection, stirring until the mixture is completely dissolved, then adding the water for injection to 5ml, and stirring uniformly to obtain a freeze-dried stock solution.
Filling the freeze-drying stock solution into a 10ml tube glass bottle, half plugging, and transferring into a freeze dryer for freezing treatment, wherein the specific freeze-drying process comprises the following steps: quickly freezing the freeze-dried stock solution to-35 ℃, keeping the freeze-dried stock solution for 1.5 hours, vacuumizing to 10Pa, heating to-12 ℃ at the speed of 1 ℃ per hour, carrying out sublimation drying treatment for 12 hours, heating to 25 ℃ at the speed of 6 ℃ per hour, carrying out desorption drying treatment for 7 hours, fully plugging, and capping to obtain the freeze-dried powder A4.
Test example
The freeze-dried powder of the antitumor drug prepared in the above example was subjected to the following stability tests:
(1) high temperature detection
45 bottles of the finished product of the example were randomly picked and placed in a drug stability testing box. Standing at 60 deg.C for 10 days, and taking samples of 0, 5, and 10 days to test various indexes including appearance, solubility and clarity. The results are detailed in Table 3.
(2) High humidity detection
Randomly extracting 45 bottles of finished products of the examples, placing each bottle in a drug stability test box after each bottle is accurately weighed, placing the bottles for 10 days under the conditions of the temperature of 25 ℃ and the Relative Humidity (RH) of 90% +/-5%, and comparing sampling detection on the 5 th day and the 10 th day with samples on the 0 th day; the appearance, redissolution and clarity of the product were examined. The results are detailed in Table 4.
(3) Intense light detection
45 bottles of finished products of the examples are randomly selected, placed in a strong light stability test box of the medicine, placed for 10 days under the condition of the illumination of 4500 +/-500 Lx, sampled and detected on the 0 th, 5 th and 10 th days respectively, and the light stability of the products is examined by comparing indexes such as appearance property, redissolution property, clarity and the like. The results are detailed in Table 5.
TABLE 3
TABLE 4
TABLE 5
As can be seen from the results of tables 3-5 above, the lyophilized powder of an antitumor drug prepared by the method of the present invention has good high temperature stability, high humidity stability and stability under strong light irradiation.
The preferred embodiments of the present invention have been described above in detail, but the present invention is not limited thereto. Within the scope of the technical idea of the invention, many simple modifications can be made to the technical solution of the invention, including combinations of various technical features in any other suitable way, and these simple modifications and combinations should also be regarded as the disclosure of the invention, and all fall within the scope of the invention.
Claims (6)
1. The lyophilized powder of the antineoplastic containing ubenimex structure comprises a pharmaceutically active component and an excipient, and is characterized in that the mass ratio of the pharmaceutically active component to the excipient is 1: 0.5-6, wherein the drug active component is a prodrug derivative of ubenimex shown in formula (I),
wherein R in the formula (I) is selected from
2. The lyophilized powder of claim 1, wherein the mass ratio of the pharmaceutically active component to the excipient is 1: 0.8-2.
3. The lyophilized powder of claim 1, wherein the excipient is at least one of mannitol, glucose, and lactose.
4. A method of preparing a lyophilized powder of any of claims 1-3, comprising the steps of:
(1) stirring the active pharmaceutical ingredient, the excipient and the water for injection until the active pharmaceutical ingredient, the excipient and the water for injection are completely dissolved to obtain a freeze-dried stock solution;
(2) pre-freezing the freeze-dried stock solution at-25 to-40 ℃ for 1 to 3 hours, vacuumizing to 5 to 30Pa after freezing, heating to-5 to-15 ℃ at the speed of 1 to 3 ℃ per hour, carrying out sublimation drying treatment for 10 to 20 hours, heating to 20 to 40 ℃ at the speed of 5 to 10 ℃ per hour, and carrying out resolution drying treatment for 5 to 10 hours.
5. The method according to claim 4, wherein the volume ratio of the total amount of the pharmaceutically active ingredient and the excipient to the water for injection is 5-20: 100.
6. the method according to claim 5, wherein the volume ratio of the total amount of the pharmaceutically active ingredient and the excipient to the water for injection is 8-15: 100.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811574582.9A CN109528664B (en) | 2018-12-21 | 2018-12-21 | Lyophilized powder containing ubenimex-antitumor drug synergistic prodrug derivative and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811574582.9A CN109528664B (en) | 2018-12-21 | 2018-12-21 | Lyophilized powder containing ubenimex-antitumor drug synergistic prodrug derivative and preparation method thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109528664A CN109528664A (en) | 2019-03-29 |
CN109528664B true CN109528664B (en) | 2021-07-06 |
Family
ID=65856668
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811574582.9A Active CN109528664B (en) | 2018-12-21 | 2018-12-21 | Lyophilized powder containing ubenimex-antitumor drug synergistic prodrug derivative and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109528664B (en) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1621042A (en) * | 2003-11-25 | 2005-06-01 | 范敏华 | Freeze dried powder injection of cytarabine and its preparation process |
CA2606658A1 (en) * | 2006-10-13 | 2008-04-13 | Mike Tyers | Compositions and methods for treating neurological disorders or damage |
CN101948507A (en) * | 2010-09-16 | 2011-01-19 | 廖年生 | Novel anti-cancer medicaments using NGR(NO2) as targeting carrier, preparation thereof and use thereof |
CN102657624A (en) * | 2012-06-01 | 2012-09-12 | 齐鲁制药有限公司 | High optical purity trans-dextro oxaliplatin lyophilized powder injection and preparation method thereof |
CN103588713A (en) * | 2013-06-07 | 2014-02-19 | 潍坊博创国际生物医药研究院 | Multi-target ubenimex prodrug derivative, as well as preparation method and application thereof |
CN107137360A (en) * | 2017-04-14 | 2017-09-08 | 鲁南制药集团股份有限公司 | A kind of injection azacitidine lyophilized formulations |
CN108635333A (en) * | 2018-07-10 | 2018-10-12 | 四川通达动物保健科技有限公司 | A kind of valnemulin hydrochloride freeze drying powder injection and preparation method thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1309354A2 (en) * | 2000-07-27 | 2003-05-14 | Rutgers, The State University | Therapeutic polyesters and polyamides |
-
2018
- 2018-12-21 CN CN201811574582.9A patent/CN109528664B/en active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1621042A (en) * | 2003-11-25 | 2005-06-01 | 范敏华 | Freeze dried powder injection of cytarabine and its preparation process |
CA2606658A1 (en) * | 2006-10-13 | 2008-04-13 | Mike Tyers | Compositions and methods for treating neurological disorders or damage |
CN101948507A (en) * | 2010-09-16 | 2011-01-19 | 廖年生 | Novel anti-cancer medicaments using NGR(NO2) as targeting carrier, preparation thereof and use thereof |
CN102657624A (en) * | 2012-06-01 | 2012-09-12 | 齐鲁制药有限公司 | High optical purity trans-dextro oxaliplatin lyophilized powder injection and preparation method thereof |
CN103588713A (en) * | 2013-06-07 | 2014-02-19 | 潍坊博创国际生物医药研究院 | Multi-target ubenimex prodrug derivative, as well as preparation method and application thereof |
CN107137360A (en) * | 2017-04-14 | 2017-09-08 | 鲁南制药集团股份有限公司 | A kind of injection azacitidine lyophilized formulations |
CN108635333A (en) * | 2018-07-10 | 2018-10-12 | 四川通达动物保健科技有限公司 | A kind of valnemulin hydrochloride freeze drying powder injection and preparation method thereof |
Non-Patent Citations (1)
Title |
---|
乌苯美司联合小剂量阿糖胞苷治疗老年急性髓系白血病疗效观察;冯林等;《现代医药卫生》;20151130;第31卷(第22期);第3382-3384页 * |
Also Published As
Publication number | Publication date |
---|---|
CN109528664A (en) | 2019-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI830262B (en) | Use of clemizole compounds for prevention and treatment of liver cancer | |
US10765660B2 (en) | Agent containing flavonoid derivatives for treating cancer and inflammation | |
CN108658983B (en) | N-benzenesulfonyl benzamide compound for inhibiting Bcl-2 protein and composition and application thereof | |
WO2008092127A1 (en) | Use of acetylated or esterificated azacytidine, decitabine, or other nucleoside analogs as oral agents for the treatment of tumors or other dysplastic syndromes sensitive to hypomethylating agents | |
CN101787064B (en) | Cytarabine derivatives and purposes thereof in resisting cancers and tumors | |
CN101735276A (en) | Water-soluble phosphate monoester derivatives and application thereof | |
EP3279201A1 (en) | Cdk inhibitor, eutectic crystal of mek inhibitor, and preparation method therefor | |
CN108148098B (en) | Gemcitabine-aromatic nitrogen mustard conjugate targeting cancer cell high-level ROS (reactive oxygen species), preparation method and medical application thereof | |
CN101302199B (en) | Guidemycin and use thereof in tumor treatment | |
CN109528664B (en) | Lyophilized powder containing ubenimex-antitumor drug synergistic prodrug derivative and preparation method thereof | |
CN107141284B (en) | Coptisine analog derivative, preparation method, pharmaceutical composition and anticancer usage | |
CN109705044B (en) | Synergistic prodrug derivative of ubenimex derivative and compound with anti-tumor activity, preparation method and application thereof | |
CN109846873B (en) | Anti-tumor medicine composition | |
CN109846818B (en) | Injection of antineoplastic medicine with ubenimex structure and preparation method thereof | |
CN114478561B (en) | Epalrestat lycorine conjugate and preparation method and application thereof | |
CN107383015B (en) | Alkylthio-terminal-group oligo-PEG-modified amino pyrazolo [3,4-d ] pyrimidine derivative and application thereof in resisting non-small cell lung cancer | |
CN112480082B (en) | Compound, preparation method and application thereof in preparation of medicine for treating small cell lung cancer | |
CN109646429B (en) | Solid dosage form containing ubenimex prodrug derivative and preparation method thereof | |
US11850239B2 (en) | MDM2 inhibitor and a platinum compound for cancer treatment | |
CN108586410B (en) | Biflavonoid compound and application thereof | |
CN102485735B (en) | 6-fructosamine-4-arylamidoquinazoline derivative and purpose thereof | |
WO2016171470A1 (en) | Bromodomain-inhibiting compounds and methods to prevent or treat a cancer | |
JP2018508495A (en) | Prodrug and pharmaceutical composition of sunitinib | |
CN110642918B (en) | Diosgenin derivative and preparation method and application thereof | |
CN110590778A (en) | 3, 10 di-p-methoxyphenyl 6, 12 diaza tetracubane compound, synthetic method and application thereof, and pharmaceutical composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |